Prothena Corp (PRTA) PT Raised to $50 at RBC Capital

June 10, 2021 5:11 PM EDT
Get Alerts PRTA Hot Sheet
Price: $49.26 +1.11%

Rating Summary:
    16 Buy, 2 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 15 | Down: 13 | New: 24
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

RBC Capital analyst Kennen MacKay raised the price target on Prothena Corp (NASDAQ: PRTA) to $50.00 (from $28.00) while maintaining an Outperform rating following Biogen's (NASDAQ: BIIB) ADUHELM approval.

The analyst commented, "We reiterate our OP rating & increase our price target to $50/ sh incorporating value to PRTA's early stage Alzheimer's Disease programs. Following the recent approval of BIIB's ADUHELM we see improved clinical/ regulatory prospects for the development of AD-directed products, and we expect significant big-biotech/pharma interest in the space. While PRTA's AD pipeline remains early (INDs in '21 & '22) we anticipate this will be a major focus of investors ahead."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

RBC Capital